23 May 2013
Keywords: biogen, idec, initiates, ph, iii, trial, adentri
Article | 01 September 2008
US drugmaker Biogen Idec has initiated a Phase III trial of intravenous Adentri (BG9928), an adenosine A1 receptor antagonist, for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 September 2008
18 August 2008
15 September 2008
© 2013 thepharmaletter.com